Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BackgroundFocused efforts of the visceral leishmaniasis elimination program have led to a drastic decline in cases, and the present challenge is disease monitoring, which this study aimed to assess.MethodsA Leishmania kinetoplastid-targeted qPCR quantified parasite load at disease presentation, and following treatment completion (n=49); an additional 80 cases were monitored after completion of treatment.ResultsThe parasite load at disease presentation was 13 461.00 (2560.00-37764.00)/µg gDNA, which upon completion of treatment reduced in 47 of 49 cases to 1(1-1)/µg gDNA, p<0.0001. In 80 cases that presented >2 months post-treatment, their parasite burden similarly decreased to 1(1-1)/µg gDNA except in 6 of 80 cases, which were qPCR positive.ConclusionIn 129 cases of visceral leishmaniasis, qPCR by quantification of parasite burden proved effective for monitoring treatment.

Original publication

DOI

10.1093/trstmh/trad103

Type

Journal

Transactions of the Royal Society of Tropical Medicine and Hygiene

Publication Date

05/2024

Volume

118

Pages

343 - 345

Addresses

Department of Pharmacology, Institute of Postgraduate Medical Education and Research, Kolkata 700020, India.

Keywords

Humans, Leishmania donovani, Leishmaniasis, Visceral, DNA, Protozoan, Antiprotozoal Agents, Treatment Outcome, Adolescent, Adult, Aged, Middle Aged, Child, Child, Preschool, Infant, Female, Male, Young Adult, Real-Time Polymerase Chain Reaction, Parasite Load